Skip to content Skip to left sidebar Skip to footer

COVID-19 Bivalent mRNA Vaccine Authorized for Primary Use

COVID-19 Bivalent mRNA Vaccine Authorized for Primary Use

CDC has taken steps to simplify COVID-19 vaccine recommendations and allow more flexibility for people at higher risk who want the option to receive an additional COVID-19 vaccine dose. COVID-19 monovalent vaccines are no longer authorized for use.
These changes include:
  • An additional updated (bivalent) vaccine dose for adults ages 65 years and older and additional doses for people who are immunocompromised.
    • Individuals ages 6 years and older who have already received a bivalent mRNA vaccine booster do not need to take any action unless they are 65 years or older or immunocompromised.
  • CDC recommends that everyone ages 6 years and older receive a bivalent mRNA COVID-19 vaccine, regardless of whether they previously completed their primary series.
    • For young children, multiple doses continue to be recommended and will vary by age, vaccine, and which vaccines were previously received.
  • Original monovalent COVID-19 vaccine is no longer authorized for use. Moving forward, bivalent mRNA vaccine is approved for the primary series.
What to do About Monovalent Waste
Monovalent vaccines in inventory and expired ancillary kits should be wasted. All wasted vaccine must be reported to PhilaVax, removed from your inventory, disposed of properly, and removed from Vaccine Finder. View the PDPH wastage guide.
The PDPH Immunization Program will share updated guidance next week when published by CDC.